Dainippon Sumitomo's Pan-Asia Trial Problem; Mitsubishi Tanabe Tries To Rebound From Earthquake: Japanese Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Dainippon Sumitomo Pharma Co. Ltd. has a lot riding on anticipated blockbuster Latuda (lurasidone); for the 2011 fiscal year, the company forecasts sales will plunge 4.6% to ¥362 billion due to sales decreases in its major products. Such is the importance of the schizophrenia drug that the company announced during its May 12 full-year earnings call a post-Latuda strategy, even though the schizophrenia drug just launched in the U.S. in February